Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
18 July 2018Website:
http://www.crinetics.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:20:00 GMTDividend
Analysts recommendations
Institutional Ownership
CRNX Latest News
Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr. Cuddihy is a board-certified physician in endocrinology, diabetes and metabolism with more than 30 years of experience spanning clinical practice and pharmaceutical industry medical affairs.
Michelle Ross, StemPoint Capital CIO, joins CNBC's Halftime Report' to discuss her latest biotech pick.
Crinetics Pharmaceuticals (CRNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Crinetics (CRNX) stock rises after achieving goals in the second late-stage study evaluating paltusotine in patients with acromegaly who are treatment-naive or not currently receiving medical therapy.
Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript
Today, we take a deeper look at Crinetics Pharmaceuticals, Inc., which has seen a significant increase in its stock price in recent months. The company's primary drug candidate, paltusotine, looks like it could become a best of breed treatment for the rare disease acromegaly. Crinetics is also evaluating paltusotine for the treatment of Carcinoid syndrome and has other compounds in development for different diseases.
Crinetics Pharmaceuticals, Inc. (CRNX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
As economic and stock market uncertainty looms, you may think at first that now is not a great time to be dabbling in speculative stocks. Yet, while the broad market may be experiencing turbulence right now, there are several stocks benefiting from company-specific catalysts that outweigh the macro issues.
- 1(current)
What type of business is Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
What sector is Crinetics Pharmaceuticals in?
Crinetics Pharmaceuticals is in the Healthcare sector
What industry is Crinetics Pharmaceuticals in?
Crinetics Pharmaceuticals is in the Biotechnology industry
What country is Crinetics Pharmaceuticals from?
Crinetics Pharmaceuticals is headquartered in United States
When did Crinetics Pharmaceuticals go public?
Crinetics Pharmaceuticals initial public offering (IPO) was on 18 July 2018
What is Crinetics Pharmaceuticals website?
https://www.crinetics.com
Is Crinetics Pharmaceuticals in the S&P 500?
No, Crinetics Pharmaceuticals is not included in the S&P 500 index
Is Crinetics Pharmaceuticals in the NASDAQ 100?
No, Crinetics Pharmaceuticals is not included in the NASDAQ 100 index
Is Crinetics Pharmaceuticals in the Dow Jones?
No, Crinetics Pharmaceuticals is not included in the Dow Jones index
When does Crinetics Pharmaceuticals report earnings?
The next expected earnings date for Crinetics Pharmaceuticals is 08 August 2024